Online Program Home
My Program

CC = Colorado Convention Center   H = Hyatt Regency Denver at Colorado Convention Center
* = applied session       ! = JSM meeting theme

Activity Details

251 Mon, 7/29/2019, 2:00 PM - 2:45 PM CC-Hall C
SPEED: Biopharmaceutical Methods and Application I, Part 2 — Contributed Poster Presentations
Biopharmaceutical Section
Chair(s): Sarah Ryan
Oral Presentations for this session.
1: Bayesian Leveraging of Historical and Concurrent Data to Assess the Contribution of a New Molecular Entity with a Delayed Effect in a Combination Survival Trial
Samson Ghebremariam, Novartis Pharmaceutical Corporation; Lisa Hampson, Novartis Pharmaceutical Corporation; Amy Racine-Poon, Novartis Pharmaceutical Corporation; Beat Neuenschwander, Novartis Pharmaceutical Corporation; Bharani Dharan, Novartis Pharmaceuticals; Kalyanee Appanna, Novartis Pharmaceutical Corporation
2: Design of Clinical Trials for Bivariate Endpoints
Junxiao Hu, University of Colorado; Patrick Blatchford, University of Colorado; John Kittelson, University of Colorado
3: Bayesian Modeling in Historical Data Borrowing on Controls in Clinical Trials
Zhuqing Yu, AbbVie Inc.; Zailong Wang, AbbVie Inc.; Lanju Zhang
4: Analysis Methods for Skewed Data Distributions
Annpey Pong
5: Identification of Potential Predictive Biomarker Candidates Through Strategic Analysis of Cytokine Profiles Across Multiple Anti-PD-1 Clinical Trials
Jeea Choi, Novartis; Ying Amanda Wang, Novartis; John Millholland, Novartis; Albert Reising, Novartis; Jan Christoph Brase, Novartis; Xiaoshan Wang, Novartis; Connie Wong, Novartis; Kitty Wan, Novartis; Yiqun Yang, Novartis; Gullu Gorgun, Novartis; Parul Patel, Novartis; Hemant Patel, Novartis
6: Precise and Accurate Power of the Rank-Sum Test for a Continuous Variable
Katie Rose Mollan, University of North Carolina Chapel Hill; Ilana Trumble, University of Colorado Denver; Sarah Reifeis, University of North Carolina at Chapel Hill; Orlando Ferrer, University of North Carolina Chapel Hill; Camden P Bay, Harvard Medical School; Pedro L. Baldoni, University of North Carolina At Chapel Hill; Michael Hudgens, University of North Carolina at Chapel Hill
7: Reducing Misclassification Effect on Dynamic Treatment Regimen (DTR) of Sequential Multiple Assignment Randomized Trial Designs (SMART)
Jun He, Virginia Commonwealth University; Roy T Sabo, Virginia Commonwealth University; Donna McClish, VCU
8: Simple Adjustment for Bias Due to Unobserved Confounding
Yiran (Bonnie) Hu, AbbVie; Hui Xie, University of Illinois at Chicago
9: Umbrella and Platform Trials: Statistical Considerations on Efficiencies and a Case Study
Xiaoyun (Nicole) Li, Merck; Cong Chen, Merck & Co., Inc; Fang Liu, Merck; Wen Li, Merck
10: Optimal Design and Analysis of Efficacy Expansion in Phase I Oncology Trials
Iris Wu, Merck & Co.; Fang Liu, Merck; Heng Zhou, Merck & Co., Inc; Cong Chen, Merck & Co., Inc
11: Evaluating the “One-Model Fits All” Approach for Modeling Clinical Trial Adverse Events
Stephanie Pan
12: How Many Imputations Are Enough When Reporting Clinical Trials?
Anders Gorst-Rasmussen, Novo Nordisk A/S
13: Meta-Analysis of Longitudinal Preclinical Efficacy Screens
William Forrest, Genentech, Inc; Bruno Alicke, Genentech; Magdalena Osinska, Genentech; Shannon Ruppert, Genentech; Michal Jakubczak, Roche; Pawel Piatkowski, Roche
14: The Application of Beta Regression for Modeling a Covariate Adjusted ROC
Xing Meng, Baylor University; Jack D. Tubbs, Baylor University
15: Examining the Replication Crisis: The Effect of Underpowered Studies and Publication Bias
Christine M. Orndahl, Virginia Commonwealth University Dept of Biostatistics; Robert A. Perera, VCU Department of Biostatistics
16: Comparison of Bayesian Network Meta-Analysis Models for Survival Data
Purvi Prajapati, Baylor University; James D Stamey, Baylor University; John Seaman, Baylor University; Michael Sonksen, Eli Lilly & Co.; Min-Hua Jen, Eli Lilly & Co.
17: Advantages of Parallel Design Over Crossover Design in the Study on Effects of Cannabis on Driving in Healthy Adults
Anya Umlauf, UC San Diego; Barth Wilsey, UC San Diego; Thomas Marcotte, UC San Diego; Florin Vaida, UC San Diego
18: Probability of Undetectable Error in Independent Dual Programming Validation for Analysis Results in Clinical Trials
Long Zheng, Takeda Pharmaceutical
19: An Extension of Cohen’s Kappa for Clustered Data and Group Sequential Testing
Mary Ryan, University of California, Irvine; Daniel L. Gillen, University of California, Irvine
20: Flexible Semiparametric Bayesian Hierarchical Model for Basket Trials
Veronica Bunn, Takeda Pharmaceuticals; Jianchang Lin, Takeda Pharmaceuticals; Rachael Liu, Takeda Pharmaceuticals